Technical Analysis for CANF - Can-Fite Biopharma Ltd Sponsored ADR (Israel)
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Historical CANF trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| 200 DMA Support | Bullish | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | -9.24% | |
| NR7 | Range Contraction | -9.24% | |
| Inside Day | Range Contraction | -9.24% | |
| Wide Bands | Range Expansion | -9.24% | |
| Up 3 Days in a Row | Strength | -9.24% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Can-Fite BioPharma, Ltd., a biotechnology company, develops drugs for the treatment of cancer and autoimmune inflammatory diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis; and has completed Phase II study for the treatment of rheumatoid arthritis and glaucoma, as well as completed Phase III study for the treatment of dry eye and Phase I study for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of hepatocellular carcinoma; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company was founded in 2000 and is based in Petach Tikva, Israel.
Medicine Biotechnology Cancer Medical Specialties Immunology Treatment Of Cancer Rheumatoid Arthritis Psoriasis Glaucoma Inflammatory Diseases Arthritis Hepatocellular Carcinoma Immunosuppressants Uveitis Biotie Therapies Treatment Of Inflammatory Diseases Treatment Of Psoriasis
Medicine Biotechnology Cancer Medical Specialties Immunology Treatment Of Cancer Rheumatoid Arthritis Psoriasis Glaucoma Inflammatory Diseases Arthritis Hepatocellular Carcinoma Immunosuppressants Uveitis Biotie Therapies Treatment Of Inflammatory Diseases Treatment Of Psoriasis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.95 |
| 52 Week Low | 1.08 |
| Average Volume | 1,773,332 |
| 200-Day Moving Average | 2.15 |
| 50-Day Moving Average | 2.04 |
| 20-Day Moving Average | 2.24 |
| 10-Day Moving Average | 2.43 |
| Average True Range | 0.24 |
| ADX | 49.23 |
| +DI | 31.50 |
| -DI | 19.26 |
| Chandelier Exit (Long, 3 ATRs ) | 2.24 |
| Chandelier Exit (Short, 3 ATRs ) | 2.46 |
| Upper Bollinger Band | 2.73 |
| Lower Bollinger Band | 1.75 |
| Percent B (%b) | 0.52 |
| BandWidth | 43.69 |
| MACD Line | 0.13 |
| MACD Signal Line | 0.13 |
| MACD Histogram | -0.0047 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.97 | ||||
| Resistance 3 (R3) | 2.97 | 2.74 | 2.85 | ||
| Resistance 2 (R2) | 2.74 | 2.56 | 2.74 | 2.81 | |
| Resistance 1 (R1) | 2.50 | 2.45 | 2.39 | 2.50 | 2.77 |
| Pivot Point | 2.27 | 2.27 | 2.21 | 2.27 | 2.27 |
| Support 1 (S1) | 2.03 | 2.09 | 1.92 | 2.03 | 1.75 |
| Support 2 (S2) | 1.80 | 1.98 | 1.80 | 1.71 | |
| Support 3 (S3) | 1.56 | 1.80 | 1.67 | ||
| Support 4 (S4) | 1.56 |
